Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$273 Mln
Revenue (TTM)
$138 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.6
Industry P/E
--
EV/EBITDA
-3.6
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-2.1
Face value
--
Shares outstanding
53,827,000
CFO
$-623.32 Mln
EBITDA
$-954.62 Mln
Net Profit
$-942.58 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Prothena (PRTA)
| -59.1 | -15.7 | -58.8 | -72.3 | -37.9 | -10.0 | -19.1 |
|
BSE Sensex*
| 4.3 | -0.9 | 10.6 | 6.0 | 16.6 | 19.4 | 11.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Prothena (PRTA)
| -39.7 | 22.0 | 311.3 | -24.1 | 53.7 | -72.3 | -23.8 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Prothena (PRTA)
|
5.7 | 273.4 | 137.9 | -110.3 | -101.1 | -22.7 | -- | 0.6 |
| 29.4 | 5,075.7 | 1,513.8 | 352.7 | 27.3 | 25.2 | 14.7 | 3.3 | |
| 12.7 | 795.8 | 0.0 | -42.1 | -- | -16.9 | -- | 2.6 | |
| 1.0 | 39.6 | 0.0 | -22.6 | -- | -- | -- | 6.0 |
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline includes birtamimab, an... investigational humanized antibody, which in phase 3 clinical trial to treat patients with AL amyloidosis; and Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer's disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer's disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland. Read more
President, CEO & Director
Dr. Gene G. Kinney Ph.D.
President, CEO & Director
Dr. Gene G. Kinney Ph.D.
Headquarters
Dublin
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Prothena Corporation plc (PRTA) stood at $ 544 Mln as on 31-Mar-25
The share price of Prothena Corporation plc (PRTA) is $5.66 (NASDAQ) as of 16-Jun-2025 16:17 EDT. Prothena Corporation plc (PRTA) has given a return of -37.94% in the last 3 years.
Prothena Corporation plc (PRTA) has a market capitalisation of $ 273 Mln as on 13-Jun-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Prothena Corporation plc (PRTA) is 0.62 times as on 13-Jun-2025, a 76% discount to its peers’ median range of 2.55 times.
Since, TTM earnings of Prothena Corporation plc (PRTA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Prothena Corporation plc (PRTA) and enter the required number of quantities and click on buy to purchase the shares of Prothena Corporation plc (PRTA).
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline includes birtamimab, an investigational humanized antibody, which in phase 3 clinical trial to treat patients with AL amyloidosis; and Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in phase 2 clinical trial for potential treatment of transthyretin amyloidosis; BMS-986446, an investigational antibody, which is in phase 2 clinical trial to treat Alzheimer's disease; PRX012, an investigational antibody, which is in phase 1 clinical trial to treat Alzheimer's disease; PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease; and PRX019, an investigational antibody, which is in phase 1 clinical trial for the potential treatment of neurodegenerative diseases. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.
The CEO & director of Dr. Gene G. Kinney Ph.D.. is Prothena Corporation plc (PRTA), and CFO & Sr. VP is Dr. Gene G. Kinney Ph.D..
There is no promoter pledging in Prothena Corporation plc (PRTA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
501
|
|
|
45
|
|
|
5
|
|
|
501
|
|
|
45
|
|
|
5
|
| Prothena Corporation plc (PRTA) | Ratios |
|---|---|
|
Return on equity(%)
|
-22.69
|
|
Operating margin(%)
|
-101.14
|
|
Net Margin(%)
|
-79.94
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Prothena Corporation plc (PRTA) was $0 Mln.
$0.58
(
